RxDoctor Payments Data

Matthew Horton

Nurse Practitioner · Grand Jct, CONPI 1669032876

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 8 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Boston Scientific at 28.6% of the total.

$690in general payments, 2019–2025

Across 8 payments — averaging $86.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$197
  • Edwards Lifesciences$121
  • Johnson & Johnson$117
  • AstraZeneca$100
  • Bridgebio Pharma, Inc.$96
  • Bristol Myers Squibb$29
  • plus $29 from 1 others

What the payments were for

  • Food & beverage$690100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$690 in reported general payments places this provider in the 80th percentile of 1,384 nurse practitioner providers in Colorado.

See all nurse practitioner providers in Colorado

Medicare billing

Part B allowed, 2024
$61,797
Medicare patients
283
Services billed
1,007

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan173$164,690
EliquisApixaban135$137,585
FarxigaDapagliflozin Propanediol136$106,983
JardianceEmpagliflozin27$30,722
XareltoRivaroxaban19$24,937
KerendiaFinerenone22$18,525
OzempicSemaglutide14$15,696
VascepaIcosapent Ethyl16$12,577
Repatha SureclickEvolocumab17$9,939
VerquvoVericiguat11$8,909
Praluent PenAlirocumab12$7,537
DapagliflozinDapagliflozin Propanediol11$5,167
CorlanorIvabradine Hcl13$4,341
Ezetimibe72$3,469
Metoprolol Succinate181$3,139

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$100$106,983136 claims
Johnson & JohnsonXarelto$117$24,93719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,384 nurse practitioner providers in Colorado.

Other nurse practitioner in Grand Jct

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →